Inhibitors of caspaseI- dependent cytokine in the treatment of neurodegenerative disorders

The present invention, chronic neurodegenerative disorders, in particular, administration progressive muscular atrophy (PMA) treatment, to a subject in need of preventing or ameliorating a specific inhibitor of caspase I- dependent cytokine comprising, such treatment to a method for the prevention or improvement. Similarly, neurodegenerative disorders, in particular, treating PMA, specific inhibitors of caspase I- dependent cytokine to prevent or improve, is disclosed herein. Furthermore, the present invention is, in a medical or pharmaceutical intervention of neurodegenerative disorders, caspase I- dependent cytokine (s) provides for the use of specific inhibitors. In particular, cytokine to be inhibited, interleukin -1 (IL-1), interleukin -18 (IL-18), interleukin -33 and interferon gamma; - selected from the group consisting of (IFN-gamma interferon gamma) it is, and most preferably, the inhibitor should be utilized in the context of the present invention, such as anakinra, a human interleukin-1 receptor antagonist (IL-1Ra). .BACKGROUND